Form 4: Castle Biosciences CEO Sells Shares Under 10b5-1 Plan
Insider Transaction Report
Castle Biosciences' President and CEO, Derek J. Maetzold, sold 5,115 shares of common stock for approximately $40.05 per share under a pre-arranged 10b5-1 plan.
Summary
- Derek J. Maetzold, President & Chief Executive Officer and Director of Castle Biosciences Inc. (CSTL), reported a sale of common stock.
- The transaction involved the disposition of 5,115 shares of common stock.
- The shares were sold at a weighted-average price of $40.049 per share.
- The total value of the shares sold was approximately $204,840.73 (5,115 shares * $40.049/share).
- The sale was executed on November 25, 2025.
- This transaction was conducted pursuant to a Rule 10b5-1 plan adopted by Mr. Maetzold on May 8, 2025.
- Following the transaction, Mr. Maetzold directly beneficially owns 45,822 shares of common stock.
- He also indirectly beneficially owns 261,372 shares through various trusts, including The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, several Maetzold 2018 Remainder Trusts, and DJM Grantor Retained Annuity Trusts.
Sentiment
Score: 5
Explanation: The filing reports a pre-scheduled insider stock sale under a Rule 10b5-1 plan, which is a routine event and does not inherently indicate positive or negative sentiment regarding the company's future prospects.
Industry Context
This is an individual insider transaction, which is a routine disclosure for publicly traded companies. It does not directly reflect broader industry trends but rather an executive's pre-planned stock disposition strategy.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Policy/Procedure Adherence | The transaction was made pursuant to a Rule 10b5-1 plan, which allows insiders to set up a pre-arranged plan to sell company stock to avoid accusations of insider trading. | 05/08/2025 | Demonstrates adherence to SEC regulations for insider trading and provides transparency regarding planned stock dispositions. |
Related Party Transactions
- Indirect beneficial ownership through various trusts where the reporting person or his family members are trustees or beneficiaries. These include The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trusts (FBO Emily Carol Kirk, Hannah Elizabeth Maetzold, John Derek Maetzold, Peter Douglas Maetzold), and DJM Grantor Retained Annuity Trusts (No. 5, No. 6, No. 7).
Stakeholder Impact
- Shareholders: A routine, pre-planned sale by a key executive. While it reduces the executive's direct holdings, the pre-planned nature mitigates concerns about market timing. The executive's total beneficial ownership remains substantial.
Key Dates
| Date | Description |
|---|---|
| 05/08/2025 | Rule 10b5-1 plan adopted by Derek J. Maetzold. |
| 11/25/2025 | Date of transaction (sale of common stock). |
| 11/26/2025 | Date the Form 4 was signed by Frank Stokes, Attorney-in-fact. |
Keywords
Castle Biosciences, CSTL, Derek J. Maetzold, Form 4, Insider Trading, Stock Sale, 10b5-1 Plan, CEO, Director
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.